6/29/23, 11:56 PM STOP-HF Pathway Feedback Search Clinical Topics Home Studies STOP HF STOP HF Disease Heart failure Trial question What is the role of screening program using brain-type natriuretic peptide and collaborative care in patients with cardiovascular risk factors? Study design Multi-center Open label RCT Population Characteristics of study participants 55.0% female N = 1374 45.0% male 1374 patients (751 female, 623 male) Inclusion criteria: patients with cardiovascular risk factors Key exclusion criteria: refused to provide informed consent, LV systolic dysfunction, history of symptomatic HF, or diagnosis compromising survival Interventions N=697 screening with BNP (with BNP 50 pg/mL undergoing echocardiography plus collaborative care between their primary care physician and specialist cardiovascular service) N=677 no routine BNP screening (usual primary care) Primary outcome https://web.pathway.md/studies/recfHcacRjL8MEC8J 1/2 6/29/23, 11:57 PM STOP-HF Pathway LV dysfunction with or without heart failure 8.7 % 8.7 6.5 % 5.3 4.3 % Significant decrease 2.2 % NNT = 29 0.0 % Screening with BNP No routine BNP screening Significant decrease in LV dysfunction with or without HF (5.3% vs. 8.7%; OR 0.55, 95% CI 0.37 to 0.82) Secondary outcomes Significant decrease in emergency hospitalization for major cardiovascular events (per 1,000 patient-years) (22.3 vs. 40.4; IRR 0.6, 95% CI 0.45 to 0.81) Significant decrease in asymptomatic LV dysfunction (4.3% vs. 6.6%; OR 0.57, 95% CI 0.37 to 0.88) No significant difference in HF (1% vs. 2.1%; OR 0.48, 95% CI 0.2 to 1.2) Conclusion In patients with cardiovascular risk factors, screening with BNP was superior to no routine BNP screening with respect to LV dysfunction with or without HF. Reference Ledwidge M, Gallagher J, Conlon C et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013 Jul 3;310(1):66-74. Open reference URL https://web.pathway.md/studies/recfHcacRjL8MEC8J 2/2